KRASG12D选择性VHL-PROTAC与节省的KRASWT和其他KRAS突变体

Eunhye Jeon1, Chan Kim1, Minjoo Ko1

  • 1Department of Medical Science, Graduate School of Medical Science, Brain Korea 21 FOUR Project, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.

概括

研究人员开发了一种名为CH091138的新型蛋白质溶解向金马 (PROTAC),可以选择性降解KRAS G12D突变蛋白,这是许多癌症的常见驱动因素,提供了一种有前途的新抗癌策略.